Hematologi
EHA 2021 Held on 10-13 June, EHA 2021 virtual congress provided new insights from the world of hema-
tology. We at BestPractice Nordic had an oppor-
tunity to meet virtually some of the leading scientists within hematology, who presented research findings at EHA.
Dr. Agoston Gyula Szabo of our Scientific Advisory Board put forward questions regarding
each study from the Nordic perspective. See the highlights below and hear the answers on bpno.no.
Data from the MonumentTAL-1 study
Dr. Amrita Y. Krishnan presented an update on phase I data from the MonumentTAL-1 study
on the safety, tolerability and efficacy of the recommended phase II dose (RP2D) of talqueta
mab in patients with relapsed and refractory multiple myeloma.
Talquetamab is a first-in-class bispecific immunoglobulin G4 antibody that binds to CD3 and GPRC5D to activate T cells to attack multiple myeloma cells. The study has shown a high
clinical response rate in patients with relapsed and refractory multiple myeloma.
In our MEDtalk Dr. Krishnan answers the following questions:
• The response rates reported here are very
impressive. Do you think responses will be durable? What is your impression?
• Is there any aspect of talquetamab treat-
ment that is problematic for patients? Any significant hair or nail issues?
• If you could choose, where would you posi-
tion talquetamab in the sequence of myeloma treatments for your patient?
Dr. Amrita Y. Krishnan, Director of Judy and Bernard Briskin Multiple Myeloma Center, Professor of Hemato logy/Hematopoietic Cell Transplantation, City of Hope Cancer Center
20
BestPractice Nordic / NO / Onkologi og Hematologi / NR. 5 / 2021
